Testing SA as a market for MAPS technology to reduce HIV risk

To address the concerns of HIV and unplanned pregnancy, researchers are developing multipurpose prevention technologies (MPTs) that aim to reduce women’s risks of HIV and provide effective contraception.

An alternative mechanism of delivery of MPTs is through intradermal delivery of a drug using microarray patches (MAPs). MAPs are an easy-to-use, self-administered, discreet delivery technology that could improve adherence to HIV PrEP and improve access to long-acting contraceptives.

Genesis was contracted by PATH to explore the hypothetical acceptability, programmatic fit and usability of MAPS technology in South Africa. We did so by engaging with potential end-users and key stakeholders through focus-group discussions and key informant interviews in three provinces in South Africa.

Understanding the perspectives of users and other stakeholders will help the PATH team and its partners develop MAPs for HIV PrEP and as an MPT to better meet users’ needs and address their concerns, particularly in low-resource settings.

Results from this study are being used to equip the PATH team with an understanding of the attitudes and perceptions of end-users and other stakeholders on features and characteristics that will make these new health products acceptable and usable for potential end-users and determine whether they would fit into the South African health system.